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Abstract
Background: PRO-CTCAE is a library of items that measure cancer treatment-related symptomatic adverse events
(NCI Contracts: HHSN261201000043C and HHSN 261201000063C). The objective of this study is to examine the
equivalence and acceptability of the three data collection modes (Web-enabled touchscreen tablet computer,
Interactive voice response system [IVRS], and paper) available within the US National Cancer Institute (NCI) Patient-
Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) measurement
system.
Methods: Participants (n = 112; median age 56.5; 24 % high school or less) receiving treatment for cancer at seven
US sites completed 28 PRO-CTCAE items (scoring range 0–4) by three modes (order randomized) at a single study
visit. Subjects completed one page (approx. 15 items) of the EORTC QLQ-C30 between each mode as a distractor.
Item scores by mode were compared using intraclass correlation coefficients (ICC); differences in scores within the
3-mode crossover design were evaluated with mixed-effects models. Difficulties with each mode experienced by
participants were also assessed.
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Results: 103 (92 %) completed questionnaires by all three modes. The median ICC comparing tablet vs IVRS was
0.78 (range 0.55–0.90); tablet vs paper: 0.81 (0.62–0.96); IVRS vs paper: 0.78 (0.60–0.91); 89 % of ICCs were ≥0.70.
Item-level mean differences by mode were small (medians [ranges] for tablet vs. IVRS = −0.04 [−0.16–0.22]; tablet vs
paper = −0.02 [−0.11–0.14]; IVRS vs paper = 0.02 [−0.07–0.19]), and 57/81 (70 %) items had bootstrapped 95 % CI
around the effect sizes within +/−0.20. The median time to complete the questionnaire by tablet was 3.4 min; IVRS:
5.8; paper: 4.0. The proportion of participants by mode who reported “no problems” responding to the
questionnaire was 86 % tablet, 72 % IVRS, and 98 % paper.
Conclusions: Mode equivalence of items was moderate to high, and comparable to test-retest reliability (median
ICC = 0.80). Each mode was acceptable to a majority of respondents. Although the study was powered to detect
moderate or larger discrepancies between modes, the observed ICCs and very small mean differences between
modes provide evidence to support study designs that are responsive to patient or investigator preference for
mode of administration, and justify comparison of results and pooled analyses across studies that employ different
PRO-CTCAE modes of administration.
Trial registration: NCT Clinicaltrials.gov identifier: NCT02158637
Keywords: PRO-CTCAE, Patient-Reported Outcomes, Symptoms, Adverse Events, Mode of Administration,
Interactive Voice Response System
Background
The US National Cancer Institute (NCI) initiated devel-
opment of a patient-reported outcome (PRO) measure-
ment system for quantifying symptomatic adverse events
in cancer clinical trials [1]. This system is intended to
complement the existing long-standing approach to cap-
turing investigator-reported adverse events using the
Common Terminology Criteria for Adverse Events
(CTCAE). Although the CTCAE provides a standard
method for clinician grading of adverse effects, add-
itional evaluation from the patient perspective is war-
ranted since approximately 10 % of the adverse effects
listed in the CTCAE are subjective symptoms that can
be best evaluated by gathering information directly from
patients. A recent systematic review confirms that clini-
cians often underestimate the incidence, severity and
distress of the symptoms experienced by cancer patients
[2]. In response to these challenges, the NCI has recently
developed and validated the Patient-Reported Outcomes
version of the Common Terminology Criteria for Ad-
verse Events (PRO-CTCAE) [1, 3]. The PRO-CTCAE
measurement system is comprised of a library of ques-
tions evaluating the various attributes (e.g., the presence,
frequency, severity, and interference with usual activ-
ities) of 78 symptoms drawn from the CTCAE [3]. The
PRO-CTCAE item library includes items that capture
the full range of symptomatic treatment effects that may
be experienced across a variety of disease sites and can-
cer treatment modalities. For more information about
PRO-CTCAE and for permission to use, visit http://
healthcaredelivery.cancer.gov/pro-ctcae/.
A survey of oncology clinical trialists and NCI repre-
sentatives identified that an essential feature of the PRO-
CTCAE measurement system is the capacity to adminis-
ter items to patients via a variety of modes including
tablet/personal computer, Interactive Voice Response
System (IVRS; i.e., automated telephone questionnaire),
and paper [4]. In response, a PRO-CTCAE software sys-
tem was developed to allow assessment via these three
modes in order to enhance its use across a variety of
study contexts and populations, including individuals
with limited literacy, limited access to the internet or
telephone, or sensory impairments. However, to have
confidence in the validity of the data collected using
these different modes and to permit pooled analyses
when different modes are used within and between stud-
ies, evidence is needed that individuals will provide the
same responses to a PRO-CTCAE item regardless of
which mode of administration is used.
A substantial number of studies of other PRO measures
have evaluated the equivalence of paper vs. screen-based
(tablet, laptop/desktop computer, or small handheld
device) administration, across many domains and
populations, and meta-analysis of these studies con-
firms high levels of reliability when paper-based and
screen-based administration is compared [5, 6]. How-
ever fewer studies have evaluated the equivalence of
visual formats (e.g., paper and screen) and aural for-
mats such as IVRS [6–13]. The adaptations made to
PRO measures to migrate from a visual format to IVRS
are classified as a moderate level of modification by re-
search guidelines [14], and thus formal quantitative evalu-
ation of mode equivalence and an assessment of user
satisfaction and usability testing are recommended. Fur-
ther, in order to allow for multiple modes within a single
study or to conduct pooled analyses of studies using
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different modes, evidence to support equivalence across
modes of administration is crucial [15]. Usability testing of
the Web-enabled touchscreen tablet computer and IVRS
modes of administration of the PRO-CTCAE system were
conducted as part of a larger study of patient and clinician
usability [16]. The purpose of this study was to examine
the between-mode equivalence and the relative acceptabil-
ity of the three available modes of PRO-CTCAE adminis-
tration in a diverse sample of patients undergoing cancer
treatment. This study was conducted as a nested
study within a large validation study of the English




Adult patients with a solid tumor or hematologic malig-
nancy, initiating or currently receiving chemotherapy,
radiation therapy, or both, at one of three U.S.-based
cancer centers and four community oncology practices
in the U.S. NCI Community Cancer Centers Program
(NCCCP) were eligible to participate in this study. The
seven sites were: Dana-Farber Cancer Institute, Boston,
MA; Memorial Sloan Kettering Cancer Center, New
York, NY; University of Texas M. D. Anderson Cancer
Center, Houston, TX; Hartford Hospital - Helen and
Harry Gray Cancer Center, Hartford, CT; Our Lady of
the Lake and Mary Bird Perkins Cancer Center, Baton
Rouge, LA; Gibbs Cancer Center, Spartanburg, SC; and
St. Joseph Hospital of Orange, Orange, CA. Potential
subjects were approached in clinical waiting areas and
invited to participate in this study. All participants could
read and comprehend English and were without clinic-
ally significant cognitive impairment based on site inves-
tigator judgment.
Enrollment was limited at the academic institutions to
specific tumor sites including breast, head, neck, or
esophageal cancer; metastatic prostate, bladder, lung, or
colorectal cancer; lymphoma or myeloma; at community
oncology practices; enrollment was open to all tumor
sites. Study sites were selected to achieve sampling di-
versity with respect to educational attainment, as well as
geographic, racial/ethnic, and socio-economic factors.
Ethics, consent, and permissions
Institutional review board approval was obtained at all
sites and at the NCI, and all participants completed writ-
ten informed consent.
PRO-CTCAE Item Library
The PRO-CTCAE item library is composed of 124 self-
report items reflecting 78 symptomatic adverse events,
with each adverse event assessed relative to one or more
attributes, including: presence/absence (P), frequency
(F), severity (S), and/or interference (I) with usual or
daily activities. The PRO-CTCAE item library includes
items that capture the full range of symptomatic treat-
ment effects that may be experienced across the full
range of cancer treatment modalities [1, 3]. We exam-
ined the mode equivalence of 28 items measuring 14
symptomatic adverse events, specifically: anxiety [F,S, I],
sad or unhappy feelings [F,S,I], constipation [S], diarrhea
[F], anorexia [S,I], nausea [F,S], vomiting [F,S], mouth or
throat sores [S,I], shortness of breath [S,I], numbness/
tingling in hands and feet [S,I], pain [F,S,I], rash [P], fa-
tigue [S,I], and insomnia [S,I]. These items were chosen
for this study, based on the high prevalence of these symp-
toms in persons undergoing cancer treatment, including
investigational treatment [17, 18]. Items measuring fre-
quency, severity, and interference with daily activities used
a 0–4 rating scale (i.e., frequency: (0) never, (1) rarely, (2)
occasionally, (3) frequently, (4) almost constantly; severity:
(0) none, (1) mild, (2) moderate, (3) severe, (4) very severe;
and interference with daily activities: (0) not at all, (1) a lit-
tle bit, (2) somewhat, (3) quite a bit, (4) very much). The
response options for presence/absence were (0) no or (1)
yes. The standard recall period for all PRO-CTCAE items
is the past 7 days.
Study Design
Participants completed the PRO-CTCAE questionnaire
in clinic by each of the three modes (Web-enabled
touchscreen tablet computer, IVRS, and paper) in a sin-
gle study visit lasting approximately 45–60 min. The
order in which each mode was to be completed was de-
termined by randomized crossover design, in which par-
ticipants were assigned in equal numbers to one of six
possible orders for completing the questionnaire in each
of the three modes, so that order effects could be identi-
fied and controlled in the analysis. The PRO-CTCAE
screen-based and IVRS questionnaires employ condi-
tional branching. For example, if a patient responds
“Never” (0) to the frequency item, the subsequent items
for that symptom assessing severity or interference with
daily activities are not asked, and in the analysis it is as-
sumed the response to these items is “None” (0) or “Not
at all” (0). The paper version of PRO-CTCAE presents
all the items for each symptomatic AE and does not in-
clude a skip pattern. Therefore, in this study a respond-
ent could be asked to complete as many as 28 items, or
in the case of screen-based and IVRS questionnaires, as
few as 14 items. To provide distraction between each of
the three questionnaires (tablet, IVRS, and paper), par-
ticipants completed the first and second half of the
European Organization for Research and Treatment of
Cancer Quality of Life Questionnaire Core-30 (EORTC
QLQ-C30) on paper [19]. This distraction was incorpo-
rated into the study design to reduce the chances that
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participants answered the duplicate questions on differ-
ent modes based on their memory of previously pro-
vided responses. The EORTC QLQ-C30 subscales are
scored on a scale of 0–100 where higher functional and
global health status/quality of life scores represent better
function and global health status/quality of life and
lower symptom scores represent a lower level of sympto-
mology [19].
The IVRS was accessed via cell phone or land line
telephone, and the paper-based questionnaire was pro-
vided on standard size pages (8.5” × 11”). The screen-
based questionnaire was completed via Web-enabled
touchscreen tablets. The tablets provided to the study
sites had a screen size of 12.2” with the exception of one
site in which the screen size was 10.5”, however this dif-
ference did not alter the presentation of the question-
naire. The screen-based version of the PRO-CTCAE is
currently designed to be presented on full-size screens
such as those found on large touchscreen tablets or
desktop computers.
Participants were shown how to use the touchscreen
tablet and IVRS by the research staff immediately prior
to beginning each questionnaire. While completing each
questionnaire, participants were required to answer
questions without assistance from others, but could re-
quest technical assistance from research staff. Demo-
graphic and clinical variables (including comorbidities
and Eastern Cooperative Oncology Group [ECOG] per-
formance status) were reported by the clinician.
To capture the time to complete the questionnaire in
each mode, research staff noted the start and end times
for the paper questionnaire, the Web-based system re-
corded the start and end time of the tablet questionnaire,
and the IVRS recorded the start and end time of each item
administered by phone. The time to complete items by
paper and screen-based modes of administration was cal-
culated as the total time divided by the number of items
the respondent completed. At the conclusion of the study
visit, participants’ experiences with each mode were soli-
cited via a structured exit interview conducted by the re-
search coordinator. Participants were asked to rate
whether they had any problems completing the question-
naire in each mode, using the response scale: no prob-
lems/some problems/a lot of problems. Participants were
also asked their preferred mode for completing question-
naires in clinic or from home. Open-ended comments
about each mode were also captured.
Sample size
The randomized crossover design was selected because
it is the most efficient, and allows for testing of order ef-
fects, mode effects, and their interactions [20]. Sample
size using the formula derived by Walter (1998) [20] was
based on the power to reject a null hypothesis that the
intraclass correlation coefficient (ICC) between a pair of
modes is less than or equal to 0.70 (p0 in the notation of
Walter [1998]) using a two-sided test with α = 0.05/81; a
conservative Bonferroni adjustment for three compari-
sons (tablet vs IVRS, tablet vs paper, and IVRS vs paper)
within each of the 27 items was applied.1 120 subjects
would provide 18 % power to detect a true ICC of 0.80
(p1 in the notation of Walter [1998]); 79 % power for an
ICC of 0.85 and >99 % power for an ICC of 0.90.
Data analysis
Item scores were compared by mode using ICCs based
on two-way analysis of variance models. The degree of
mode equivalence indicated by the ICC was compared
to a widely used benchmark value of ≥ 0.70 [21]. The
ICCs of the across-mode comparisons including the
screen-based questionnaire (i.e. tablet vs IVRS and tablet
vs paper) were also compared to the test-retest reliability
of the screen-based questionnaire from the validation
study, in which the screen-based questionnaire was com-
pleted on consecutive business days a total of two times
[3]. The use of parametric statistics (means and correla-
tions) in the analysis of ordinal scale data is well-
supported in studies with sufficiently large samples that
the sampling distribution of these statistics is approxi-
mately normal [22, 23]. In simulation studies using 1000
bootstrap samples of the same sample size as this study,
the sampling distributions of mean scores and correla-
tions were approximately normally distributed, even for
items with extreme floor effects (data not shown). Fur-
ther, sensitivity analyses employing Wilcoxon signed-
rank tests for pairwise mean rank comparisons produced
results consistent with the presented results based on
parametric methods (data not shown). Differences in
scores by mode were evaluated with mixed-effects
models for the 3-mode crossover design. The models in-
cluded terms for mode, order, mode-by-order inter-
action, and sequence [24]. Effect sizes of the item mean
differences were calculated based on Dunlop et al. 1996
[25] with bootstrapped 95 % confidence intervals; effect
sizes less than 0.20 were considered acceptable [14].
Exploratory analyses were conducted to identify
whether differences in scores by mode varied by partici-
pant characteristics or symptom severity. A mixed-
effects model was estimated, pooling data across items;
the model included terms for mode, order, mode-by-
order interaction, sequence, the covariate of interest,
and the mode-by-covariate interaction. Participant char-
acteristics were gender; white vs non-white; age group
(20–44, 45–64, and 65–84 years); education level;
frequency of using computer to check email; physical
functioning, role functioning, cognitive functioning,
emotional functioning, social functioning, and global
health status/quality of life, as measured by the EORTC
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QLQ-C30 subscales; ECOG performance status; limita-
tions in manual dexterity due to peripheral neuropathy
(average response across three modes to PRO-CTCAE
item for severity of numbness or tingling in hands and
feet, categorized as 0 vs. ≥1) or history of arthritis; can-
cer type; and current use of medications that may affect
memory or cognition including chemotherapy in the
past 2 weeks, opioid analgesics, sleep aids, hormone
therapy, and medications for anxiety or depression. The
covariate of symptom severity was defined as the PRO-
CTCAE item score dichotomized as none or mild (0–1)
versus moderate, severe, or very severe (2–4).
Descriptive statistics were used to summarize the time
to complete items in each mode. Univariate analyses via
linear regression with a single independent variable iden-
tified demographic or clinical characteristics associated
with the time required to complete PRO-CTCAE items.
Univariate predictors significant at the p < .10 level were
introduced into the multivariable linear regression
models using step-wise forward selection. These analyses
were conducted separately for each mode of administra-
tion. Participant responses to the closed-ended questions
in the structured exit interview were summarized using
descriptive statistics, and any open-ended comments
about each mode were summarized qualitatively.
Results
Between February and May 2012, 112 participants com-
pleted the PRO-CTCAE questionnaire in at least one
mode and 103 (92 %) completed the questionnaire in
each of the three modes. Median age was 56.5 years
(range 24–81 years) and 59.8 % were female (see Table 1).
Self-reported race included 76.8 % white and 17 % black
or African American; 9.8 % reported Hispanic/Latino
ethnicity. Participants had a range of educational attain-
ment: 53.6 % had completed at least college, 20.5 % had
completed some college, 17.0 % had completed high
school or GED, and 7.1 % had not completed high
school. A majority (82 %) used a computer to check
email or browse the internet at least several times a
week. Approximately 40 % of the sample had ECOG per-
formance status of 1 (32.1 %) or 2+ (8.9 %), reflecting
some degree of functional impairment. Cancer types
included: breast (34.8 %), lung/head/neck (31.3 %),
gastrointestinal (11.6 %), hematological (11.6 %), and
genitourinary/gynecologic (9.8 %). In the past two weeks,
62.5 % had received chemotherapy, 33.0 % had received
radiation, and 0.9 % had undergone surgery. The sample
was symptomatic in the past 7 days: 64 % reported ex-
periencing pain, 75 % had fatigue, tiredness, or lack of
energy, 47 % had loose or watery stools, and 49 % had
nausea, each defined by a symptom score ≥ 1 as reported
via the tablet questionnaire. The means and standard de-
viations of EORTC QLQ-C30 global health status/quality
of life and functional scale scores were: Global Health
Status/Quality of Life 63.8 (SD = 20.9), Physical Func-
tioning 81.9 (SD = 20.4), Role Functioning 74.7 (SD =
27.9), Emotional Functioning 75.7 (SD = 22.3), and Social
Functioning 69.7 (SD = 27.2).
The median ICCs at the item level were: tablet vs
IVRS: 0.78 (range 0.55 to 0.90); tablet vs paper: 0.81
(range 0.62 to 0.96); and IVRS vs paper: 0.78 (range 0.60
to 0.91). The ICC and its 95 % confidence interval (CI)
for each PRO-CTCAE item for the comparison between
modes are shown in Table 2. A majority (89 %) of the
ICCs were ≥0.70. Most ICCs (88 %) had a two-sided
95 % CI lower bound greater than or equal to 0.60, and
44 % of ICCs had a two-sided 95 % CI lower bound
greater than or equal to 0.70. Kappa statistics of agree-
ment for the presence/absence item rash were 0.79 for
tablet vs IVRS, 0.75 for tablet vs paper, and 0.66 for
IVRS vs paper (all p < 0.001).
The median ICC of tablet vs tablet (test-retest reliabil-
ity) for the set of items included in this mode equiva-
lence analysis was 0.80 (range 0.55 to 0.86) [3]. The
mode-equivalence ICC for tablet vs IVRS and tablet vs
paper for each of the 27 items was within or above the
95 % CI of the test-retest reliability ICC for 48/54 com-
parisons (27/54 were within the 95 % CI and 21/54 were
greater than the 95 % CI upper bound). For 6/54 com-
parisons the mode-equivalence ICC was below the 95 %
CI lower bound of the test-retest reliability ICC.
For each PRO-CTCAE item, the median between-
mode difference in the mean scores comparing tablet vs
IVRS, i.e., tablet minus IVRS, was −0.04 (range −0.16 to
0.22), while for tablet vs paper it was −0.02 (range −0.11
to 0.14), and for IVRS vs paper it was 0.02 (range −0.07
to 0.19). The between-mode difference in mean scores
and 95 % confidence interval around that mean for each
PRO-CTCAE item is shown in Table 3. Further, the ef-
fect sizes of the differences in scores were all less than
0.20. The median effect size for the comparison of tablet
vs IVRS was −0.04 (range −0.16 to 0.12), for tablet vs
paper was −0.02 (range −0.11 to 0.13), and for IVRS vs
paper was 0.02 (range −0.09 to 0.17). The lower and
upper bounds of bootstrapped 95 % confidence intervals
around the effect sizes were within +/−0.2 for 57/81
(70 %) comparisons, within +/−0.3 for 79/81 (98 %)
comparisons, and within +/−0.4 for 81/81 (100 %) com-
parisons. Using linear mixed models, participant demo-
graphics, functioning, global health status/quality of life,
or symptom severity were not associated with differ-
ences in between-mode mean scores.
The time to complete PRO-CTCAE items by mode is
shown in Table 4. The average time to complete an item
by Web-enabled touchscreen tablet was 11.1 seconds
(SD = 8.4), by IVRS was 16.3 seconds (SD = 6.3), and by
paper was 10.3 seconds (SD = 5.8). For each mode,
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Table 1 Patient characteristics
Characteristic No. of Patients (N = 112) Percent
Age (in years)





Hispanic or Latino 11 9.8
Not Hispanic or Latino 97 86.6
Unknown or Not reported 4 3.6
Race
White 86 76.8
Black or African American 19 17.0
Asian 4 3.6
Native Hawaiian or Pacific Islander 2 1.8
Unknown or Not reported 1 0.9
Education
High school or less 27 24.1
Some college 23 20.5
College graduate or more 60 53.6
Unknown or Not reported 2 1.8
Disease
Breast 39 34.8
Lung, head or neck 35 31.3
Gastrointestinal 13 11.6
Genitourinary or Gynecologic 11 9.8
Hematological 13 11.6








None of the above in past 2 weeks 4 3.6
Use of computer to check e-mail or browse internet
Never 8 7.1
Less than once a week 4 3.6
Once or several times a week 19 17.0
At least once a day 79 70.5
Unknown/Not reported 2 1.8
Abbreviation: ECOG Eastern Cooperative Oncology Group
Bennett et al. Health and Quality of Life Outcomes  (2016) 14:24 Page 6 of 12
multivariable linear regression models employing step-
wise forward selection were used to identify characteris-
tics associated with the average time to complete a
PRO-CTCAE item. Time to complete items by tablet
varied by age group (b = 2.70, p = 0.039); time to complete
items by IVRS varied by history of arthritis (b = 3.48,
p = 0.027); and time to complete items by paper varied by
the following: EORTC QLQ-C30 Cognitive Functioning
(b = −0.06, p = 0.016), EORTC QLQ-C30 Role Function-
ing (b = −0.05, p = 0.017), and age (b = 2.33, p = 0.006).
These differences are very small: for example, a difference
between age groups of 2.70 s per item corresponds to an
additional 1.8 min to complete twenty items for people over
65 compared to people under 45. A 30 point difference in
EORTC QLQ-C30 Cognitive Functioning (scored 0–100) is
associated with a 0.6 min difference in completing twenty
items.
The proportion of participants reporting any problems
completing the PRO-CTCAE questionnaire in each mode
is presented in Table 5. In the structured exit interview,
98 % reported ‘no problem’ with the paper questionnaire;
86 % had ‘no problem’ with the tablet questionnaire, and
72 % had ‘no problem’ with the IVRS phone question-
naire. 10 % of participants reported having ‘some prob-
lems’ with the tablet questionnaire. Difficulties included a
slow internet connection, malfunctioning of the PRO-
CTCAE system feature respondents can use to note add-
itional symptoms, and two participants were unfamiliar
Table 2 PRO-CTCAE item intraclass correlation by tablet, IVRS and paper modes of administration
PRO-CTCAE Item ICC (95 % CI)
Mode Equivalence Test – Retesta
Tablet vs. IVRS Tablet vs. Paper IVRS vs. Paper Tablet vs. Tablet
Anxiety (F) 0.77 (0.68–0.83) 0.76 (0.67–0.83) 0.72 (0.61–0.79) 0.78 (0.68–0.85)
Anxiety (S) 0.75 (0.65–0.82) 0.72 (0.62–0.80) 0.73 (0.63–0.80) 0.70 (0.58–0.80)
Anxiety (I) 0.69 (0.58–0.77) 0.74 (0.64–0.81) 0.68 (0.57–0.77) 0.83 (0.75–0.89)
Constipation (S) 0.71 (0.60–0.79) 0.76 (0.66–0.83) 0.80 (0.73–0.86) 0.83 (0.74–0.89)
Decreased appetite (S) 0.73 (0.62–0.80) 0.80 (0.72–0.86) 0.82 (0.73–0.87) 0.81 (0.71–0.87)
Decreased appetite (I) 0.78 (0.69–0.84) 0.80 (0.72–0.86) 0.70 (0.60–0.79) 0.80 (0.71–0.87)
Fatigue, tiredness, or lack of energy (S) 0.74 (0.64–0.81) 0.76 (0.67–0.83) 0.74 (0.64–0.81) 0.77 (0.66–0.85)
Fatigue, tiredness, or lack of energy (I) 0.65 (0.53–0.75) 0.70 (0.59–0.79) 0.60 (0.46–0.70) 0.79 (0.69–0.86)
Insomnia (S) 0.83 (0.76–0.88) 0.94 (0.92–0.96) 0.79 (0.71–0.85) 0.65 (0.50–0.76)
Insomnia (I) 0.76 (0.67–0.83) 0.84 (0.77–0.89) 0.81 (0.74–0.87) 0.72 (0.59–0.81)
Loose or watery stools (F) 0.80 (0.73–0.86) 0.81 (0.74–0.87) 0.76 (0.67–0.83) 0.55 (0.38–0.69)
Mouth or throat sores (S) 0.82 (0.75–0.87) 0.87 (0.82–0.91) 0.71 (0.61–0.79) 0.82 (0.73–0.88)
Mouth or throat sores (I) 0.55 (0.41–0.67) 0.62 (0.48–0.72) 0.61 (0.47–0.71) 0.81 (0.72–0.87)
Nausea (F) 0.87 (0.81–0.91) 0.90 (0.85–0.93) 0.87 (0.82–0.91) 0.79 (0.70–0.86)
Nausea (S) 0.85 (0.78–0.89) 0.87 (0.82–0.91) 0.86 (0.80–0.90) 0.84 (0.76–0.89)
Numbness/tingling in hands/feet (S) 0.89 (0.85–0.92) 0.89 (0.84–0.92) 0.86 (0.81–0.91) 0.80 (0.70–0.86)
Numbness/tingling in hands/feet (I) 0.81 (0.73–0.86) 0.85 (0.79–0.90) 0.80 (0.73–0.86) 0.55 (0.37–0.68)
Pain (F) 0.90 (0.86–0.93) 0.93 (0.90–0.95) 0.91 (0.87–0.94) 0.83 (0.75–0.89)
Pain (S) 0.88 (0.83–0.92) 0.89 (0.85–0.92) 0.86 (0.81–0.90) 0.82 (0.73–0.88)
Pain (I) 0.77 (0.68–0.84) 0.83 (0.77–0.88) 0.77 (0.68–0.83) 0.84 (0.76–0.89)
Sad or unhappy feelings (F) 0.77 (0.68–0.83) 0.80 (0.72–0.85) 0.76 (0.67–0.83) 0.73 (0.61–0.81)
Sad or unhappy feelings (S) 0.77 (0.69–0.84) 0.79 (0.71–0.85) 0.79 (0.71–0.85) 0.63 (0.48–0.75)
Sad or unhappy feelings (I) 0.69 (0.58–0.78) 0.70 (0.59–0.78) 0.72 (0.61–0.80) 0.76 (0.65–0.84)
Shortness of breath (S) 0.85 (0.79–0.89) 0.87 (0.82–0.91) 0.90 (0.85–0.93) 0.70 (0.56–0.80)
Shortness of breath (I) 0.84 (0.77–0.89) 0.73 (0.63–0.81) 0.72 (0.61–0.80) 0.66 (0.52–0.77)
Vomiting (F) 0.82 (0.75–0.87) 0.96 (0.94–0.97) 0.87 (0.82–0.91) 0.81 (0.72–0.88)
Vomiting (S) 0.82 (0.75–0.87) 0.92 (0.88–0.94) 0.83 (0.76–0.88) 0.79 (0.70–0.86)
Note: The mode equivalence of the presence/absence item assessing rash was evaluated with Kappa statistics and results are reported in the text
Abbreviations: PRO-CTCAE Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events, F Frequency, S Severity, I Interference,
ICC Intraclass Correlation Coefficient, CI Confidence Interval, IVRS Interactive Voice Response System
aTest-retest data were obtained from the validation study [3] (see Methods)
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with using a tablet computer. Twenty-seven percent of
participants reported having ‘some problem’ with the
IVRS phone questionnaire. The comments regarding
IVRS revealed that some had difficulties with cell phone
reception in the hospital building and therefore found it
hard to hear the questions being asked via IVRS. The pro-
portions of respondents who stated they would be com-
fortable using paper, tablet, and IVRS for completing a
questionnaire from home were 95 %, 87 %, and 75 %, re-
spectively. A majority of participants had a stated
Table 3 PRO-CTCAE Item scores by tablet, IVRS and paper modes of administration
PRO-CTCAE Item Item Score Difference in Item Scores by Mode
Mean (SD) Mean Difference (95 % CI)
Tablet Tablet – IVRS Tablet – Paper IVRS – Paper
Anxiety (F) 1.41 (0.90) −0.11 (−0.24, 0.03) −0.02 (−0.15, 0.11) 0.08 (−0.05, 0.21)
Anxiety (S) 0.62 (0.84) −0.03 (−0.16, 0.09) 0.00 (−0.13, 0.13) 0.03 (−0.09, 0.16)
Anxiety (I) 1.20 (0.84) −0.14 (−0.27, −0.01) −0.06 (−0.20, 0.07) 0.08 (−0.05, 0.21)
Constipation (S) 0.80 (0.99) −0.12 (−0.26, 0.02) 0.01 (−0.13, 0.15) 0.13 (−0.01, 0.27)
Decreased appetite (S) 0.62 (0.92) −0.14 (−0.28, −0.01) 0.05 (−0.08, 0.18) 0.19 (0.06, 0.32)
Decreased appetite (I) 0.93 (1.03) −0.03 (−0.16, 0.10) 0.07 (−0.06, 0.20) 0.10 (−0.04, 0.23)
Fatigue, tiredness, or lack of energy (S) 1.40 (1.17) −0.16 (−0.30, −0.02) −0.04 (−0.18, 0.10) 0.12 (−0.02, 0.26)
Fatigue, tiredness, or lack of energy (I) 1.53 (1.11) −0.07 (−0.23, 0.10) 0.11 (−0.05, 0.28) 0.18 (0.02, 0.35)
Insomnia (S) 0.96 (1.19) −0.05 (−0.17, 0.08) 0.05 (−0.08, 0.18) 0.10 (−0.03, 0.22)
Insomnia (I) 1.32 (1.22) −0.08 (−0.22, 0.06) −0.11 (−0.26, 0.03) −0.03 (−0.17, 0.11)
Loose or watery stools (F) 0.79 (0.99) −0.01 (−0.13, 0.11) −0.01 (−0.13, 0.11) 0.00 (−0.11, 0.12)
Mouth or throat sores (S) 0.21 (0.56) −0.03 (−0.12, 0.07) 0.01 (−0.08, 0.10) 0.04 (−0.06, 0.13)
Mouth or throat sores (I) 0.40 (0.74) −0.01 (−0.12, 0.10) −0.08 (−0.19, 0.04) −0.07 (−0.18, 0.05)
Nausea (F) 0.92 (1.16) −0.08 (−0.19, 0.03) −0.05 (−0.15, 0.06) 0.03 (−0.07, 0.14)
Nausea (S) 0.75 (0.95) −0.09 (−0.19, 0.01) −0.06 (−0.17, 0.04) 0.02 (−0.08, 0.12)
Numbness/tingling in hands/feet (S) 0.70 (1.06) −0.13 (−0.23, −0.04) 0.00 (−0.09, 0.10) 0.14 (0.04, 0.23)
Numbness/tingling in hands/feet (I) 0.89 (1.03) 0.08 (−0.04, 0.19) 0.04 (−0.08, 0.16) −0.03 (−0.15, 0.08)
Pain (F) 1.34 (1.29) −0.05 (−0.15, 0.06) 0.02 (−0.09, 0.13) 0.07 (−0.04, 0.17)
Pain (S) 1.06 (1.19) 0.01 (−0.10, 0.12) −0.02 (−0.14, 0.09) −0.03 (−0.14, 0.08)
Pain (I) 1.25 (1.20) −0.04 (−0.19, 0.11) −0.03 (−0.18, 0.13) 0.01 (−0.15, 0.16)
Rash (P) 0.11 (0.32) −0.03 (−0.08, 0.02) −0.04 (−0.09, 0.01) −0.01 (−0.06, 0.04)
Sad or unhappy feelings (F) 1.44 (0.98) 0.12 (0.00, 0.24) 0.14 (0.02, 0.26) 0.02 (−0.10, 0.14)
Sad or unhappy feelings (S) 0.70 (0.91) 0.03 (−0.08, 0.14) −0.01 (−0.12, 0.10) −0.04 (−0.15, 0.07)
Sad or unhappy feelings (I) 1.11 (0.83) 0.05 (−0.08, 0.18) 0.01 (−0.12, 0.15) −0.03 (−0.17, 0.10)
Shortness of breath (S) 0.51 (0.83) −0.04 (−0.11, 0.04) −0.05 (−0.12, 0.03) −0.01 (−0.09, 0.07)
Shortness of breath (I) 0.57 (0.77) −0.07 (−0.19, 0.05) −0.10 (−0.22, 0.02) −0.03 (−0.15, 0.09)
Vomiting (F) 0.29 (0.65) −0.02 (−0.08, 0.05) −0.02 (−0.09, 0.04) 0.00 (−0.07, 0.06)
Vomiting (S) 0.27 (0.64) 0.00 (−0.07, 0.07) −0.06 (−0.13, 0.02) −0.06 (−0.13, 0.02)
Abbreviations: PRO-CTCAE Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events, F Frequency, S Severity, I Interference,
P Presence/Absence, SD Standard Deviation, CI Confidence Interval, IVRS Interactive Voice Response System
Table 4 Time to complete PRO-CTCAE items, by mode
Mode Number of items completed Seconds per item Seconds per item
Mean (SD) Mean (SD) Median (25th p – 75th p)
Tablet 22.6 (3.4) 11.1 (8.4) 9.1 (7.4–11.6)
IVRS 22.5 (3.5) 16.3 (6.3) 15.8 (13.0–18.2)
Paper 26.9 (2.6) 10.3 (5.8) 8.6 (6.4–12.9)
Abbreviations: PRO-CTCAE Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events, IVRS Interactive Voice Response System, SD
Standard Deviation
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preference to complete questionnaires from home using
the tablet (59 %), while 23 % preferred paper, 10 % pre-
ferred IVRS, and 8 % had no preference.
Discussion
This study employed a randomized crossover design to
compare PRO-CTCAE item scores across three modes
of data collection – Web-enabled touchscreen tablet
computer, IVRS, and paper, in a large diverse U.S. sam-
ple of patients undergoing treatment for cancer. In sum-
mary, the mode-equivalence of items was moderate to
high, and similar to test-retest reliability. Differences in
mean scores by mode were generally trivial in size, and
were not moderated by clinical or demographic charac-
teristics, including gender, education, race/ethnicity or
symptom severity. This study was designed to identify
large differences between modes; employing stricter cri-
teria (that is, requiring that the lower bound of the 95 %
CI around the ICC be greater than 0.70 for true ICCs
below 0.85) would have made the necessary sample size
infeasible. Although the study was not powered to iden-
tify ICCs below 0.85 as being statistically greater than
0.70, the observed point estimates of between-mode
ICCs and very small mean differences provide evidence
to support study designs that employ multiple modes of
administration.
The equivalence of PRO-CTCAE scores by mode ob-
served here is consistent with the findings of mode-
equivalence studies of other PRO measures commonly
used in cancer. A mode equivalence study of the EORTC
QLQ-C30 which examined the equivalence of multi-
item subscales across screen-based, IVRS and paper
found ICCs ranged from 0.79 to 0.90 with 95 % lower
confidence intervals greater than 0.70 [7]. A mode
equivalence study of the Patient-Reported Outcomes
Measurement Information System® (PROMIS®) adult
measures of physical function, fatigue, and depression,
which compared personal computer administration with
IVRS, paper, and personal digital assistant in a random-
ized cross-over design, observed ICCs ranging from 0.85
to 0.94 and no evidence of differences in score level [8].
The EORTC QLQ-C30 and PROMIS® short forms were
evaluated at the level of multi-item scales, whereas the
PRO-CTCAE is composed of individual items that are
not combined into scale scores. Scales with a small num-
ber of items will tend to have lower measurement reli-
ability and similarly, the ICC of the between-mode
comparisons will also be lower [13, 26]. However, given
that symptomatic adverse event reporting – the purpose
of the PRO-CTCAE, generally requires surveillance on a
wide range of toxicities at frequent intervals, longer
questionnaires would produce unacceptable respondent
burden.
The design and sampling plan of this mode equiva-
lence study had a number of strengths. Data were col-
lected from a diverse sample of U.S. cancer patients,
reflecting a range of race/ethnicity (22.4 % were non-
white), education level (44.6 % did not have a college de-
gree), adult ages, treatment settings, and cancer types,
and the sampling was enriched for patients with poor
performance status who were symptomatic. The ran-
domized factorial design employed in the data collection
enabled direct comparisons of responses by mode within
patient. The study was successful in achieving a high
rate of questionnaire completion for all three modes
(92 % completed all three modes). This was one of the
anticipated benefits of having the questionnaires com-
pleted in one study visit. Most importantly, there would
also be no change in health status between assessments.
A distractor questionnaire, one page of the EORTC
QLQ-C30, was employed in the study design between
modes so that respondents would not be completing the
PRO-CTCAE questionnaires one directly after the other.
The inclusion of the EORTC QLQ-C30 functional and
health status/QOL subscales and comprehensive clinical
data including current medications and treatment, also
provided the opportunity to evaluate several important
hypothesized covariates in the analysis of scores by
mode and the time to complete each mode.
Three caveats must be considered in interpreting our
findings about the mode equivalence of PRO-CTCAE
items. First, it is possible that despite the use of dis-
tractor questionnaires between modes, participants
recalled their responses to the previous set of questions.
In between assessments, the participant completed the
distraction task and was oriented to using the next
mode, which took approximately 10 min. This study was
designed so that assessments were completed on the
same day in order to avoid differences in scores being
due to changes in symptomology, and it was not feasible
for assessments to be completed several hours apart be-
cause that would have significantly extended partici-
pants’ study visits, thus imposing an unacceptable level
of burden in patients undergoing active cancer treat-
ment. Second, comparisons of the between-mode reli-
ability statistics and test-retest reliability statistics must
consider that the test-retest reliability was based on
assessments gathered approximately 1–3 days apart,
Table 5 Participant report of problems completing PRO-CTCAE
items, by mode
Mode “No problems” “Some problems” “A lot of problems”
Tablet 94 (86 %) 11 (10 %) 4 (4 %)
IVRS 79 (72 %) 29 (27 %) 1 (1 %)
Paper 108 (98 %) 2 (2 %) 0 (0 %)
Abbreviations: PRO-CTCAE Patient-Reported Outcomes version of the Common
Terminology Criteria for Adverse Events, IVRS Interactive Voice
Response System
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whereas all three mode equivalence assessments were
gathered within a 1 hour period when comparatively lit-
tle fluctuation in symptom severity would be expected,
and that the 95 % CI of the test-retest reliability is
dependent on the sample size. In addition, the between-
mode and the within-mode (test-retest) reliability esti-
mates were derived in different samples, though both
were drawn from the same study population in terms of
the eligibility criteria and recruitment strategy. Third, an
unavoidable limitation of statistical estimates of
between-mode differences is that the agreement of two
assessments depends on the distribution of symptoms
scores in the patient sample. Prior studies have found
higher levels of agreement between ratings when both
assessments are “0” (symptom is absent) but lower levels
of agreement in the upper ranges of the severity scale
[27]. Therefore the level of agreement or reliability be-
tween two assessments may be higher when a larger
proportion of the sample does not have the symptom in
question. However, it is a strength of our study that ap-
proximately half of respondents were experiencing com-
mon cancer symptoms, including pain, fatigue, diarrhea,
and nausea.
Across all three modes, PRO-CTCAE items were com-
pleted rapidly. It should be noted that estimation of the
total time to complete a questionnaire by each mode de-
pends upon the number of items presented to the re-
spondent. Further, because paper questionnaires do not
incorporate conditional branching or skip patterns, as
do screen-based and IVRS questionnaires, a participant
completing a paper questionnaire would generally have
to complete more items. For example, in a 28-item ques-
tionnaire with conditional branching, a respondent may
only complete 20 items. Thus, because the conditional
branching present when the questionnaire is completed
by electronic modes leads to variation in the number of
items completed by the respondent, we estimated the
time to complete a certain number of items, rather than
the time to complete a questionnaire that may contain a
varying number of items. Based on our study, we esti-
mate that completing twenty PRO-CTCAE items would
take on average 3.4 min by paper, 3.7 min by Web-
enabled touchscreen tablet computer, and 5.4 min by
IVRS. As an example of an estimate of respondent bur-
den for human subjects research applications, 75 % of
the sample would complete twenty items in 4.3 min by
paper, in 3.8 min by Web-enabled touchscreen tablet
computer, and in 6.1 min by IVRS. There was no evi-
dence of clinically meaningful variation in completion
times by participant characteristics, including impair-
ments in physical or cognitive functioning. Our findings
suggest that completion of PRO-CTCAE items is gener-
ally not laborious, even for those respondents who may
have some degree of functional limitation.
The proportions of respondents who stated that
they would be comfortable using paper, Web-enabled
touchscreen tablet, and IVRS for completing a ques-
tionnaire from home were 95 %, 87 %, and 75 %, re-
spectively. Further, 98 % reported ‘no problem’ with
the paper questionnaire; 86 % had ‘no problem’ with
Web-enabled touchscreen tablet, and 72 % had ‘no
problem’ with the IVRS questionnaire. Some study
participants experienced technical difficulties with cell
phone reception and Wi-Fi-based computer connec-
tions within the clinics where the data collection took
place.2 Because of the size and construction of many
large institutional medical buildings, connectivity is-
sues may be a key consideration for in-clinic PRO
data collection. It is likely that the participant prefer-
ences for each mode reported in this study were in-
fluenced in part by technical issues experienced in
our participating clinics. These stated preferences may
not be generalizable to at-home reporting or clinic
settings without connectivity issues.
The rate of missing data in this study was extremely low
in part because questionnaires were completed in clinic as
part of a study visit. The potential for missing data when
questionnaires are completed outside the clinic setting, in-
cluding the potential for variable rates of missing data
across modes, should be considered in the design and im-
plementation of cancer clinical trials that employ PRO-
CTCAE to collect symptomatic adverse events.
Conclusion
Our study results describe the equivalence of PRO-
CTCAE across three modes of data collection both
within- and between-participants, and the findings are
consistent with other studies examining the mode
equivalence of other PRO measures. We observed mod-
erate to high levels of agreement across modes, and pro-
vide evidence of the acceptability of paper, Web-enabled
touchscreen tablet, and IVRS modes of administration to
a majority of respondents. Although the study was pow-
ered to detect moderate or larger discrepancies between
modes, these results support study designs that are re-
sponsive to varying patient or investigator preference for
mode of administration, and justify pooled analyses or
comparison of results across studies that employ differ-
ent PRO-CTCAE modes of administration.
Endnotes
1One additional item, measuring the presence of rash
(yes/no) was assessed using Kappa statistics of agree-
ment and was not included in this count.
2To address difficulties in hearing the recorded ques-
tions, particularly in a clinic where there can be a lot of
background noise, technical adjustments have been
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made to improve the fidelity of the audio component of
the PRO-CTCAE IVRS.
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